Topical corticosteroid phobia in atopic dermatitis

International feasibility study of the TOPICOP score

J. F. Stalder*, H. Aubert, E. Anthoine, M. Futamura, D. Marcoux, M. A. Morren, M. Trzeciak, Z. Szalai, K. Veres, M. Deleuran, C. Vestergaard, F. Boralevi, C. Y. Chu, L. De Raeve, Svensson, R. Fölster-Holst, M. Buchner, R. Takaoka, V. Aoki, P. Chernyshov & 11 others L. Chernyshova, D. F. Murrell, C. Zhao, C. D. Mckinster, L. Von Kobyletzky, L. Eichenfield, C. Totri, P. Lio, J. Seneschal, L. Moret, S. Barbarot

*Corresponding author for this work

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined the feasibility of applying the validated TOPICOP score for assessing TCS phobia across different countries. Methods: This was a prospective multicentre feasibility study conducted in 21 hospitals in 17 countries. Patients >3 months of age with atopic dermatitis or their parents or legal representatives completed a validated translation of the TOPICOP questionnaire in the country's native language. Respondents also completed questionnaires collecting opinions about the feasibility and acceptability of the TOPICOP questionnaire. Results: A total of 1564 participants in 15 countries were included in the analysis. 81% of respondents considered the questions clear or very clear, and 79% reported that it took less than 5 minutes to complete. Each of the individual items in the TOPICOP questionnaire was considered to be not at all difficult to answer by 49% to 74% of participants. The mean global TOPICOP score was 44.7%±20.5. Mean TOPICOP subscores were 37.0±22.8% for knowledge and beliefs, 54.7±27.8% for fears and 50.1±29.1% for behaviours. Global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of TCS phobia and different drivers for each country. Conclusions: The TOPICOP score can be feasibly applied across countries and may therefore be useful for obtaining qualitative and quantitative data from international studies and for adapting patient education and treatment.

Original languageEnglish (US)
Pages (from-to)1713-1719
Number of pages7
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume72
Issue number11
DOIs
StatePublished - Jan 1 2017

Fingerprint

Phobic Disorders
Feasibility Studies
Atopic Dermatitis
Adrenal Cortex Hormones
Patient Education
Multicenter Studies
Fear
Surveys and Questionnaires
Language
Parents
Therapeutics

Keywords

  • adherence
  • atopic dermatitis
  • corticosteroid

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Stalder, J. F., Aubert, H., Anthoine, E., Futamura, M., Marcoux, D., Morren, M. A., ... Barbarot, S. (2017). Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score. Allergy: European Journal of Allergy and Clinical Immunology, 72(11), 1713-1719. https://doi.org/10.1111/all.13189
Stalder, J. F. ; Aubert, H. ; Anthoine, E. ; Futamura, M. ; Marcoux, D. ; Morren, M. A. ; Trzeciak, M. ; Szalai, Z. ; Veres, K. ; Deleuran, M. ; Vestergaard, C. ; Boralevi, F. ; Chu, C. Y. ; De Raeve, L. ; Svensson ; Fölster-Holst, R. ; Buchner, M. ; Takaoka, R. ; Aoki, V. ; Chernyshov, P. ; Chernyshova, L. ; Murrell, D. F. ; Zhao, C. ; Mckinster, C. D. ; Von Kobyletzky, L. ; Eichenfield, L. ; Totri, C. ; Lio, P. ; Seneschal, J. ; Moret, L. ; Barbarot, S. / Topical corticosteroid phobia in atopic dermatitis : International feasibility study of the TOPICOP score. In: Allergy: European Journal of Allergy and Clinical Immunology. 2017 ; Vol. 72, No. 11. pp. 1713-1719.
@article{16ce6398174b45ddacaf4f52891598b6,
title = "Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score",
abstract = "Background: Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined the feasibility of applying the validated TOPICOP score for assessing TCS phobia across different countries. Methods: This was a prospective multicentre feasibility study conducted in 21 hospitals in 17 countries. Patients >3 months of age with atopic dermatitis or their parents or legal representatives completed a validated translation of the TOPICOP questionnaire in the country's native language. Respondents also completed questionnaires collecting opinions about the feasibility and acceptability of the TOPICOP questionnaire. Results: A total of 1564 participants in 15 countries were included in the analysis. 81{\%} of respondents considered the questions clear or very clear, and 79{\%} reported that it took less than 5 minutes to complete. Each of the individual items in the TOPICOP questionnaire was considered to be not at all difficult to answer by 49{\%} to 74{\%} of participants. The mean global TOPICOP score was 44.7{\%}±20.5. Mean TOPICOP subscores were 37.0±22.8{\%} for knowledge and beliefs, 54.7±27.8{\%} for fears and 50.1±29.1{\%} for behaviours. Global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of TCS phobia and different drivers for each country. Conclusions: The TOPICOP score can be feasibly applied across countries and may therefore be useful for obtaining qualitative and quantitative data from international studies and for adapting patient education and treatment.",
keywords = "adherence, atopic dermatitis, corticosteroid",
author = "Stalder, {J. F.} and H. Aubert and E. Anthoine and M. Futamura and D. Marcoux and Morren, {M. A.} and M. Trzeciak and Z. Szalai and K. Veres and M. Deleuran and C. Vestergaard and F. Boralevi and Chu, {C. Y.} and {De Raeve}, L. and Svensson and R. F{\"o}lster-Holst and M. Buchner and R. Takaoka and V. Aoki and P. Chernyshov and L. Chernyshova and Murrell, {D. F.} and C. Zhao and Mckinster, {C. D.} and {Von Kobyletzky}, L. and L. Eichenfield and C. Totri and P. Lio and J. Seneschal and L. Moret and S. Barbarot",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/all.13189",
language = "English (US)",
volume = "72",
pages = "1713--1719",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "11",

}

Stalder, JF, Aubert, H, Anthoine, E, Futamura, M, Marcoux, D, Morren, MA, Trzeciak, M, Szalai, Z, Veres, K, Deleuran, M, Vestergaard, C, Boralevi, F, Chu, CY, De Raeve, L, Svensson, Fölster-Holst, R, Buchner, M, Takaoka, R, Aoki, V, Chernyshov, P, Chernyshova, L, Murrell, DF, Zhao, C, Mckinster, CD, Von Kobyletzky, L, Eichenfield, L, Totri, C, Lio, P, Seneschal, J, Moret, L & Barbarot, S 2017, 'Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score', Allergy: European Journal of Allergy and Clinical Immunology, vol. 72, no. 11, pp. 1713-1719. https://doi.org/10.1111/all.13189

Topical corticosteroid phobia in atopic dermatitis : International feasibility study of the TOPICOP score. / Stalder, J. F.; Aubert, H.; Anthoine, E.; Futamura, M.; Marcoux, D.; Morren, M. A.; Trzeciak, M.; Szalai, Z.; Veres, K.; Deleuran, M.; Vestergaard, C.; Boralevi, F.; Chu, C. Y.; De Raeve, L.; Svensson; Fölster-Holst, R.; Buchner, M.; Takaoka, R.; Aoki, V.; Chernyshov, P.; Chernyshova, L.; Murrell, D. F.; Zhao, C.; Mckinster, C. D.; Von Kobyletzky, L.; Eichenfield, L.; Totri, C.; Lio, P.; Seneschal, J.; Moret, L.; Barbarot, S.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, No. 11, 01.01.2017, p. 1713-1719.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Topical corticosteroid phobia in atopic dermatitis

T2 - International feasibility study of the TOPICOP score

AU - Stalder, J. F.

AU - Aubert, H.

AU - Anthoine, E.

AU - Futamura, M.

AU - Marcoux, D.

AU - Morren, M. A.

AU - Trzeciak, M.

AU - Szalai, Z.

AU - Veres, K.

AU - Deleuran, M.

AU - Vestergaard, C.

AU - Boralevi, F.

AU - Chu, C. Y.

AU - De Raeve, L.

AU - Svensson,

AU - Fölster-Holst, R.

AU - Buchner, M.

AU - Takaoka, R.

AU - Aoki, V.

AU - Chernyshov, P.

AU - Chernyshova, L.

AU - Murrell, D. F.

AU - Zhao, C.

AU - Mckinster, C. D.

AU - Von Kobyletzky, L.

AU - Eichenfield, L.

AU - Totri, C.

AU - Lio, P.

AU - Seneschal, J.

AU - Moret, L.

AU - Barbarot, S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined the feasibility of applying the validated TOPICOP score for assessing TCS phobia across different countries. Methods: This was a prospective multicentre feasibility study conducted in 21 hospitals in 17 countries. Patients >3 months of age with atopic dermatitis or their parents or legal representatives completed a validated translation of the TOPICOP questionnaire in the country's native language. Respondents also completed questionnaires collecting opinions about the feasibility and acceptability of the TOPICOP questionnaire. Results: A total of 1564 participants in 15 countries were included in the analysis. 81% of respondents considered the questions clear or very clear, and 79% reported that it took less than 5 minutes to complete. Each of the individual items in the TOPICOP questionnaire was considered to be not at all difficult to answer by 49% to 74% of participants. The mean global TOPICOP score was 44.7%±20.5. Mean TOPICOP subscores were 37.0±22.8% for knowledge and beliefs, 54.7±27.8% for fears and 50.1±29.1% for behaviours. Global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of TCS phobia and different drivers for each country. Conclusions: The TOPICOP score can be feasibly applied across countries and may therefore be useful for obtaining qualitative and quantitative data from international studies and for adapting patient education and treatment.

AB - Background: Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined the feasibility of applying the validated TOPICOP score for assessing TCS phobia across different countries. Methods: This was a prospective multicentre feasibility study conducted in 21 hospitals in 17 countries. Patients >3 months of age with atopic dermatitis or their parents or legal representatives completed a validated translation of the TOPICOP questionnaire in the country's native language. Respondents also completed questionnaires collecting opinions about the feasibility and acceptability of the TOPICOP questionnaire. Results: A total of 1564 participants in 15 countries were included in the analysis. 81% of respondents considered the questions clear or very clear, and 79% reported that it took less than 5 minutes to complete. Each of the individual items in the TOPICOP questionnaire was considered to be not at all difficult to answer by 49% to 74% of participants. The mean global TOPICOP score was 44.7%±20.5. Mean TOPICOP subscores were 37.0±22.8% for knowledge and beliefs, 54.7±27.8% for fears and 50.1±29.1% for behaviours. Global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of TCS phobia and different drivers for each country. Conclusions: The TOPICOP score can be feasibly applied across countries and may therefore be useful for obtaining qualitative and quantitative data from international studies and for adapting patient education and treatment.

KW - adherence

KW - atopic dermatitis

KW - corticosteroid

UR - http://www.scopus.com/inward/record.url?scp=85019941555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019941555&partnerID=8YFLogxK

U2 - 10.1111/all.13189

DO - 10.1111/all.13189

M3 - Article

VL - 72

SP - 1713

EP - 1719

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 11

ER -